New hope for a rare, scarring disease: major trial tests promising drug

NCT ID NCT03295383

Recruiting now Disease control Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

Summary

This study is testing which of two powerful drugs works better and is safer for people with severe mucous membrane pemphigoid, a rare autoimmune disease that causes painful blisters and scarring on moist body surfaces like the eyes and throat. About 130 participants will be randomly assigned to receive either rituximab or cyclophosphamide to see which one leads to better remission and fewer side effects. The goal is to find a more effective way to control this serious condition and prevent its devastating complications, like blindness.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SEVERE FORMS OF MUCOUS MEMBRANE PEMPHIGOID are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

APHM La Timone
RECRUITING

Marseille, France

Contact

Contact
APHP Avicennes
RECRUITING

Paris, France

Contact

Contact
APHP Bichat
RECRUITING

Paris, France

Contact

Contact
APHP Cochin
RECRUITING

Paris, France

Contact

Contact
APHP Henri Mondor
RECRUITING

Paris, France

Contact

Contact
APHP Pitié Salpétrière
RECRUITING

Paris, France

Contact

Contact
APHP Saint-Louis
RECRUITING

Paris, France

Contact

Contact
Brest University Hospital
RECRUITING

Brest, France

Contact

Contact
CH Argenteuil
RECRUITING

Argenteuil, France

Contact

Contact
CH Le Mans
RECRUITING

Le Mans, France

Contact

Contact
CH Quimper
RECRUITING

Quimper, France

Contact

Contact
CHU Amiens
RECRUITING

Amiens, France

Contact

Contact
CHU Angers
RECRUITING

Angers, France

Contact

Contact
CHU Bordeaux
RECRUITING

Bordeaux, France

Contact

Contact
CHU Caen
RECRUITING

Caen, France

Contact

Contact
CHU Clermont Ferrand
RECRUITING

Clermont-Ferrand, France

Contact

Contact
CHU Dijon
RECRUITING

Dijon, France

Contact

Contact
CHU Lille
RECRUITING

Lille, France

Contact

Contact
CHU Montpellier
RECRUITING

Montpellier, France

Contact

Contact
CHU Nantes
RECRUITING

Nantes, France

Contact

Contact
CHU Nice
RECRUITING

Nice, France

Contact

Contact
CHU Rennes
RECRUITING

Rennes, France

Contact

Contact
CHU Tours
RECRUITING

Tours, France

Contact

Contact
CHU de Limoges
RECRUITING

Limoges, France

Contact

Contact
CHU de Reims
RECRUITING

Reims, France

Contact

Contact
CHU saint-Etienne
RECRUITING

Saint-Etienne, France

Contact

Contact
HCL
RECRUITING

Lyon, France

Contact

Contact

Contact

Conditions

Explore the condition pages connected to this study.

SEVERE FORMS OF MUCOUS MEMBRANE PEMPHIGOID